1
|
Fen Y, Xinxin M, Yalan Y, Xu Z, Zhongsheng L, Shixiong S, Xinyan C, Zhenzhen W, Wei Z, Xiaolei W. The effect of a low-color-temperature-based yellow light source on the prevention of phlebitis induced by chemotherapy. Biomater Sci 2022; 10:909-914. [PMID: 35079753 DOI: 10.1039/d1bm01189h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In recent years, light therapy has been gradually applied to the treatment of inflammation. Different from conventional high-color-temperature light sources, low-color-temperature yellow light (1900 K) without a blue light spectrum was selected as the light source to research its preventive effects on chemotherapy-induced phlebitis in this study. Based on a series of inflammatory characterization experiments, the results manifested that the reasonable utilization of 1900 K yellow light had a good effect on the prevention of phlebitis. This study shows that this is a feasible and promising method for preventing phlebitis and relieving pain, while providing a theoretical basis for the further investigation of the anti-inflammatory effects on phlebitis.
Collapse
Affiliation(s)
- Yu Fen
- College of Chemistry, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China.,Institute of Advanced Materials, East China Jiaotong University, Nanchang, Jiangxi, 330013, P.R.China
| | - Miao Xinxin
- The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| | - Yang Yalan
- Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| | - Zhao Xu
- Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| | - Lv Zhongsheng
- Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| | - Shen Shixiong
- Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| | - Cheng Xinyan
- College of Chemistry, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| | - Weng Zhenzhen
- College of Chemistry, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| | - Zhang Wei
- College of Chemistry, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| | - Wang Xiaolei
- College of Chemistry, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China.,Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi, 330088, P.R.China
| |
Collapse
|
2
|
Mueller BU, Seipel K, Bacher U, Pabst T. Autologous Transplantation for Older Adults with AML. Cancers (Basel) 2018; 10:cancers10090340. [PMID: 30235847 PMCID: PMC6162649 DOI: 10.3390/cancers10090340] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 09/17/2018] [Accepted: 09/17/2018] [Indexed: 12/21/2022] Open
Abstract
While the majority of patients with acute myeloid leukemia (AML) are above the age of 65 years at diagnosis, the outcome of older AML patients remains disappointing. Even if standard intensive chemotherapy induces morphologic complete remission (CR1), relapses in older AML patients are common leading to poor long-term survival outcomes. Since autologous hematopoietic stem cell transplantation (HCT) offers distinct anti-leukemic effectiveness while avoiding graft-versus-host disease associated with allogeneic transplantation, it represents an option for consolidation treatment in selected older AML patients. However, prospective studies in older AML patients assessing the benefit of autologous HCT compared to chemotherapy consolidation or allogeneic transplantation are lacking. Consequently, clinicians face the dilemma that there is considerable ambiguity on the most appropriate consolidation treatment for older AML patients in CR1. This review highlights the possible role of autologous HCT for consolidation in older AML patients reaching CR1 after induction treatment.
Collapse
Affiliation(s)
- Beatrice U Mueller
- Department of BioMedical Research, University of Bern, 3010 Berne, Switzerland.
| | - Katja Seipel
- Department of BioMedical Research, University of Bern, 3010 Berne, Switzerland.
| | - Ulrike Bacher
- Department of Hematology, University of Bern, 3010 Berne, Switzerland.
| | - Thomas Pabst
- Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Berne, Switzerland.
| |
Collapse
|
3
|
Montag G, Stopper H, Ngo QA, Hintzsche H. The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine. Curr Cancer Drug Targets 2018; 19:222-230. [PMID: 29714145 DOI: 10.2174/1568009618666180430142233] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Revised: 03/05/2018] [Accepted: 04/17/2018] [Indexed: 01/11/2023]
Abstract
BACKGROUND Vinca alkaloids are important cancer drugs belonging to the class of antimitotic agents. The most commonly used substances are vinblastine and vincristine, other compounds are vinorelbine and vinflunine. All of them are very effective drugs but their use is limited by severe side-effects including neurotoxicity and bone marrow depression. Therefore, it is very important to develop novel vinca alkaloids with similar efficacy but lower toxicity. METHODS Here, we analyzed two new compounds, 4-chlorochablastine and 4-chlorochacristine, with regard to their biological activity. These novel compounds were applied to a leukemia cell line at clinically relevant concentrations. For comparison, the established vinca alkaloids vinblastine, vincristine, vinorelbine, and vinflunine were also tested. RESULTS Both novel substances decreased cellular proliferation. Apoptosis was found to be increased using two different methods reflecting early and late apoptosis. Cell cycle analysis revealed a clear decrease in G1-cells and an increase in G2/M-cells indicating an arrest in mitosis. In general, 4- chlorochablastine and 4-chlorochacristine caused these effects at concentrations higher than those needed for vinblastine, vincristine, and vinorelbine, but the potency was approximately in the range of vinflunine. CONCLUSION Taken together, the results show first indications that these novel vinca alkaloids might be effective and that they warrant further analysis.
Collapse
Affiliation(s)
- Gracia Montag
- Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Str. 9, 97078 Würzburg, Germany
| | - Helga Stopper
- Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Str. 9, 97078 Würzburg, Germany
| | - Quoc Anh Ngo
- Institute of Chemistry, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, CauGiay, Hanoi, Vietnam
| | - Henning Hintzsche
- Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Str. 9, 97078 Würzburg, Germany.,Bavarian Health and Food Safety Authority, Eggenreuther Weg 43, 91058 Erlangen, Germany
| |
Collapse
|
4
|
Ilarionova M, Todorov D, Timcheva K, Dudov A. Studies on Combined Experimental Antitumor Drug Therapy. An Attempt to Overcoming the Natural Drug Resistance. BIOTECHNOL BIOTEC EQ 2014. [DOI: 10.1080/13102818.2002.10819168] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
5
|
Schnerch D, Schmidts A, Follo M, Udi J, Felthaus J, Pfeifer D, Engelhardt M, Wäsch R. BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy. Haematologica 2013; 98:1886-95. [PMID: 23812934 DOI: 10.3324/haematol.2013.087452] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Spindle poison-based therapy is of only limited benefit in acute myeloid leukemia while lymphoblastic leukemia/lymphoma responds well. In this study, we demonstrated that the spindle assembly checkpoint protein BubR1 was down-regulated in the vast majority of cases of acute myeloid leukemia whereas its expression was high in lymphoblastic cells. Correct function of the spindle assembly checkpoint is pivotal in mediating mitotic delay in response to spindle poisons. Mitotic delay by the spindle assembly checkpoint is achieved by inhibition of anaphase-promoting complex-dependent proteolysis of cyclin B and securin. We demonstrated a link between the repression of the spindle assembly checkpoint protein BubR1 in acute myeloid leukemia and the limited response to spindle poison. In accordance with its established role as an anaphase-promoting complex-inhibitor, we found that repression of BubR1 was associated with enhanced anaphase-promoting complex activity and cyclin B and securin degradation, which leads to premature sister-chromatid separation and failure to sustain a mitotic arrest. This suggests that repression of BubR1 in acute myeloid leukemia renders the spindle assembly checkpoint-mediated inhibition of the anaphase-promoting complex insufficient, which facilitates completion of mitosis in the presence of spindle poison. As both direct and BubR1-mediated restoration of cyclin B expression enhanced response to spindle poison, we propose that the downstream axis of the spindle assembly checkpoint is a promising target for tailored therapies for acute myeloid leukemia.
Collapse
|
6
|
Kolb EA, Steinherz PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 2003; 17:1967-72. [PMID: 14513046 DOI: 10.1038/sj.leu.2403097] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We report the results of a phase 2 nonrandomized single-arm trial of a combination therapy for relapsed or refractory leukemia. From January 1999 to June 2002, 28 patients with multiple relapsed or refractory acute leukemia received a combination of topotecan, vinorelbine, thiotepa, dexamethasone, and, for patients with an M3 marrow on day 7, gemcitabine. A total of 14 patients had pre-B-ALL (acute lymphoblastic leukemia), three had T-cell leukemia, nine acute myeloblastic leukemia (AML), and two biphenotypic leukemia. In all, 13 patients achieved a significant response (10 complete responses and three partial responses). Among the responders, five had pre-B-ALL, two had T-cell leukemias, five had AML, and one had biphenotypic leukemia. In total, 10 of these patients subsequently underwent hematopoietic stem cell transplantation, and four are alive without disease. One patient died, while in remission, of complications resulting from an episode of sepsis and pneumonia that occurred during topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine (TVTG) reinduction. Other toxicities included grade 4 neutropenia in all patients and transient grade 2 hepatotoxicity in 10 patients (36%). In summary, we report that 47% of heavily pretreated pediatric patients with multiply relapsed or refractory leukemia achieved a significant response after therapy on the TVTG protocol. Further studies are warranted to evaluate the role of the TVTG combination in the treatment of leukemia.
Collapse
Affiliation(s)
- E A Kolb
- Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | |
Collapse
|